| protein
| ELK1 member of ETS oncogene family, ELK1 ( |
|
p75 nerve growth factor receptors ( |
|
vav 1 guanine nucleotide exchange factor, VAV1 ( |
|
AP kinase-interacting kinase 1 Mnk1 and Mnk2 ( |
|
MAP kinase phosphatase 3, MKP3 ( |
|
PYST2dual specificity protein phosphatase PYST2 ( |
|
PTP-SL and STEP ( |
|
p90 ribosomal S6 kinase RSK1, RSK2 and RSK3 ( |
|
topoisomerase IIalpha proteins ( |
|
phosphorylates beta-arrestin1 ( |
|
mitogen-activated protein kinase 5, MPK5 |
|
HePTP ( |
|
MEK kinase 1, MEKK1 ( |
|
signal transducer and activator of transcription 5, STAT5 ( |
|
Histone deacetylase 4, HDAC4 ( |
|
MAPK/ERK kinase 1, MEK1 and MAPK/ERK kinase 2, MEK2 ( |
|
Mitogen-activated protein (MAP) kinase phosphatase 1, MKP-1/CL100 |
|
synuclein and Elk-1 ( |
|
ceramide ( |
|
p53 ( |
|
insulin receptor, IR ( |
|
AP-1 dimers composed of diverse Jun and Fos family proteins ( |
|
phosphoprotein enriched in astrocytes 15, PEA15 |
|
hyaluronan binding protein 1, HABP1 ( |
|
NGFI-B ( |
|
9-cis retinoid X receptor alpha, RXR alpha ( |
|
estrogen receptor alpha, Era ( |
|
transducer of ERBB2, TOB ( |
|
nuclear assembly factor 1 homolog (S. cerevisiae), NAF1 ( |
|
immediately early gene X-1, IEX-1 ( |
|
caveolin-1, CAV1 ( |
|
epidermal growth factor receptor, EGFR ( |
|
E3 identified by differential display, EDD ( |
|
MAP kinase Mxi2 ( |
|
inhibits caspase-9 activity by direct phosphorylation ( |
|
MAPK phosphatase-7, MKP-7 ( |
|
RSK1 ( |
|
paxillin, PXN ( |
|
LIM-only protein FHL2 in cardiomyocytes ( |
|
Polo-like kinase-3, Plk3 ( |
|
vinexin beta ( |
|
NIMA (never in mitosis gene a)-related kinase 2a, Nek2A ( |
|
FGFR-signaling adaptor SNT2 ( |
|
p21 protein (Cdc42/Rac)-activated kinase 1, PAK1 ( |
|
death-associated protein kinase, DAPK ( |
|
dual specificity phosphatase 5, DUSP5 ( |
|
dual specificity protein phosphatase PAC-1 ( |
|
cell division cycle 25 homolog C (S. pombe), CDC25C ( |
|
progesterone receptor, PR and MSK1( |
|
death effector domain, DED ( |
|
class II, major histocompatibility complex transactivator, CIITA ( |
|
HIF1A is a substrate for MAPK1 |
|
HSPA8 is a potential interacting protein of MAPK1 |
|
MAPK1 phosphorylates PARD3 and inhibits its binding with KIF3A, thereby controlling PARD3 transport and neuronal polarity |
|
PRKCDBP facilitates signal transduction to MAPK1 by anchoring caveolae to the membrane skeleton of the plasma membrane via MYO1C |
|
AKT1, MAPK1, and IKK1/2 phosphorylate BCL3 |
|
PCBP1 can act as a suppressor of tumor in prostate epithelial cells by inhibiting MAPK1 expression |
|
| knockout studies including MAPK1 revealed some | |
associations with abnormal placental development, leading |
|
to intrauterine growth restriction and intrauterine |
|
death of null mice |
|
disrupted Mapk1/mapk3 in mouse granulosa cells provide in vivo evidence that these kinases are necessary for LH-induced oocyte resumption of meiosis, ovulation, and luteinization |
|
double knock-out newborn pups for Erk1 and Erk2 survived for not more one day, appeared normal just after parturition, displayed intracerebral hemorrhages with varying location and severity, ventricular zones and corpus callosum did not develop properly and nuclear morphology in some brain regions were markedly aberrant ( |
|
double knock-out mice deficient for Erk2 in the central nervous system, with ubiquitous homozygous deletion of Erk1 were neonatally lethal ( |
